Welcome to our dedicated page for Medpace Holdings SEC filings (Ticker: MEDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical research moves fast, and so does Medpace Holdings. Investors tracking contract backlog, net new business awards, or the founder’s periodic share sales need more than a PDF dump. This page brings every Medpace SEC filing together with context, giving you Medpace SEC filings explained simply.
Searching for the latest Medpace quarterly earnings report 10-Q filing or craving the Medpace annual report 10-K simplified? Our AI reads each document the moment it hits EDGAR, translating CRO jargon—screening rates, site-activation metrics, margin expansion—into plain English. The same engine sends alerts on Medpace insider trading Form 4 transactions, so you see leadership’s moves before the market fully reacts. A scroll-free dashboard keeps everything organized while understanding Medpace SEC documents with AI becomes effortless.
Use these tools to:
- Track Medpace Form 4 insider transactions real-time and spot buying or selling trends
- Dig into backlog changes with our Medpace earnings report filing analysis
- Decode 8-K announcements—Medpace 8-K material events explained in seconds
- Review the Medpace proxy statement executive compensation without wading through tables
- Stay current on Medpace executive stock transactions Form 4 alongside other filings
Whether you’re modelling revenue per headcount or comparing CRO margins, Stock Titan’s AI-powered summaries, expert context and real-time updates turn dense disclosures into clear, actionable knowledge.
Medpace Holdings, Inc. (MEDP) filed a Form 144 indicating an intended sale of 7,500 common shares through Fidelity Brokerage Services. The shares have an aggregate market value of $3.38 million, implying a per-share reference price of roughly $450 based on the data provided.
• Approximate sale date: 07/28/2025 on Nasdaq
• Shares outstanding: 28,093,026, so the proposed sale represents about 0.03 % of shares outstanding.
• Shares were acquired on 10/24/2023 via stock-option exercise paid in cash.
• No other sales have been reported by this filer in the past three months.
The signer certified no undisclosed material adverse information and affirmed compliance with Rule 10b5-1, if applicable. No further financial results or company-level disclosures accompany this notice.
Medpace Holdings, Inc. (MEDP) – Form 144 filing discloses a proposed sale of up to 3,000 common shares through Fidelity Brokerage Services on or about 28 Jul 2025. At the filing’s stated aggregate market value of US$1.35 million, the sale equates to roughly US$450 per share and represents only about 0.01 % of the 28,093,026 shares outstanding.
The seller—whose name is not listed—acquired the shares directly from the issuer via three events: (i) vesting of 1,823 restricted shares on 28 Feb 2024, (ii) exercise of 1,000 stock-option shares on 6 May 2022, and (iii) exercise of 177 stock-option shares on 27 Oct 2020. No securities were sold by this person during the past three months, and the standard representation affirms no knowledge of undisclosed adverse information.
Because Form 144 is only a notice of intent, execution is not guaranteed. Given the modest size relative to the public float and absence of additional operational or financial disclosures, the filing is unlikely to be materially impactful for MEDP’s near-term fundamentals but does add a datapoint on insider sentiment.
FAQ
What is the current stock price of Medpace Holdings (MEDP)?
What is the market cap of Medpace Holdings (MEDP)?
